Form 8-K - Current report:
SEC Accession No. 0001213900-24-094976
Filing Date
2024-11-06
Accepted
2024-11-06 16:00:26
Documents
13
Period of Report
2024-11-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0220098-8k_emmaus.htm   iXBRL 8-K 26513
  Complete submission text file 0001213900-24-094976.txt   194275

Data Files

Seq Description Document Type Size
2 XBRL LABEL FILE emma-20241104_lab.xml EX-101.LAB 34240
3 XBRL PRESENTATION FILE emma-20241104_pre.xml EX-101.PRE 22369
4 XBRL SCHEMA FILE emma-20241104.xsd EX-101.SCH 3030
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0220098-8k_emmaus_htm.xml XML 3359
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

EIN.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 241430751
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)